Pressmeddelanden, rapporter och bolagsmeddelande för Eevia Health

Eevia Health Abp har meddelat att inga teckningsoptioner av serie TO1 har utnyttjats för att teckna aktier i bolaget.

Tingsrätten i Södra Österbotten, Finland, har den 4 september beslutat att försätta Eevia Health Abp i konkurs. Advokat Valteri Vuorenmaa vid Advokatbyrå Fenno i Seinäjoki har utsetts till konkursförvaltare.

Eevia Health Plc har haft ekonomiska svårigheter efter att ha förlorat en huvudkund och misslyckats med att få extern finansiering trots omstruktureringar och stöd från aktieägare. När ytterligare finansiering nekades under sommaren 2025, insåg företaget att det inte fanns någon realistisk återhämtningsväg. Omstruktureringsförsöken misslyckades på grund av dålig likviditet. Styrelsen bedömde att det finns värde i företagets tillgångar, men att dessa inte kan realiseras. Efter att potentiella investerare drog sig ur och finansieringsansökningar avslogs, beslutade styrelsen att ansöka om konkurs som det bästa alternativet. Eevia Health Plc grundades 2017 och specialiserar sig på hållbara bioaktiva extrakt från nordiska växter och bär, med fokus på hälsa och välmående. Företaget noterades på Spotlight Stock Market i juni 2021.

The agenda for the Annual General Meeting (AGM) of Eevia Health includes opening the meeting, verifying its legality, and recording attendance. The financial statements and auditor's report for 2024 will be presented, with a proposal to transfer the net loss to retained earnings and not pay dividends. The meeting will address the discharge of liability for the Board and CEO, and a recommendation for voluntary liquidation and election of an administrator. If unresolved, the number of Board members will be decided, with a proposal for five members. Remuneration for Board members and the auditor will be restated, with auditor fees proposed to be paid as invoiced. An auditor will be elected, and the meeting will close. Documents for the meeting, including financial statements and proposal documentation, are pending publication. The meeting is scheduled for September 15th, with documents available online and at the meeting. Minutes will be accessible from September 17th. Participants must be registered shareholders by September 2, 2025, to attend. Registration for the meeting is required by September 10, 2025, via email or mail. Instructions are provided for nominee-registered shareholders and those with shares registered at Euroclear Sweden AB. Proxy representation is allowed, with proxy documents to be submitted by September 15, 2025. Eevia Health, founded in 2017, produces bioactive compounds from wild-harvested plant materials in Finland and Sweden. The company is listed on the Spotlight Stock Market in Sweden and focuses on sustainable practices.

The company has received customer sales orders exceeding EUR 2.5 million recently and is negotiating new contracts for 2026 with global brands. However, its current financial situation hinders the execution of these opportunities. Restructuring efforts, including relocating production to reduce costs, are delayed due to a lack of short-term liquidity. The company plans to sell redundant equipment but is unsure if this will provide enough funds to continue operations and pay liabilities. Despite asset write-downs, auditors still question the asset values, raising solvency concerns. Management is exploring options like equity injections and strategic collaborations to continue operations. The Board recommends voluntary liquidation to protect creditor interests but remains open to new opportunities that may benefit creditors and shareholders. For more information, contact Stein Ulve, CEO of Eevia Health Plc. Eevia Health specializes in sustainable bioactive extracts from Nordic plants, focusing on health-related ingredients for global nutraceutical brands. Founded in 2017, the company is listed on the Spotlight Stock Market in Sweden.

Eevia is adjusting its financial calendar due to delays in obtaining an unqualified auditor’s report and finalizing the 2024 financial statement. The Q2-2025 Interim Report publication is postponed from August 21 to August 29, 2025, to prevent misrepresentations if the 2024 financial statements and balance sheet change. Eevia plans to release its statutory financial statements and auditor’s report on August 29, 2025, contingent on receiving the auditor’s report. The Annual General Meeting (AGM) will be held on September 15, 2025, with the notice issued on August 21 and documents to follow shortly. Eevia Health Plc, established in 2017, produces bioactive compounds from wild-harvested plants in Finland and Sweden for global dietary supplements and food brands. The company emphasizes sustainability and transparency in its operations and was listed on the Spotlight Stock Market in 2021. For more information, contact CEO Stein Ulve or visit their website.

Eevia Health Plc issued TO 1 warrants as part of a Rights Issue in August 2024 and announced that the last day to trade these warrants will be on August 26, 2025. Eevia Health, founded in 2017, produces bioactive compounds from plant materials, primarily sourced from Finnish and Swedish forests. Their products are sold globally as ingredients for dietary supplements and food brands. The company emphasizes sustainable harvesting and operates a production facility in Finland, promoting a short value chain and low carbon footprint. Eevia Health was listed on the Spotlight Stock Market in Sweden in June 2021. For more information, contact Stein Ulve, CEO, via email or phone.

Eevia Health has canceled its agreement to sell intellectual property related to its main eye-health compound to Havu Health Oy for 800,000 euros. The cancellation occurred because Havu Health did not meet the conditions of the sale, which required either payment for the IP or converting the payment into shares, making Eevia the dominant owner. As neither condition was fulfilled, the intellectual property remains with Eevia. Eevia Health, founded in 2017, focuses on creating bioactive compounds from renewable plant materials for health purposes and operates a green-chemistry production facility in Finland. The company is listed on the Spotlight Stock Market in Sweden. For more information, contact Stein Ulve, CEO of Eevia Health.

Terry Virts resigned from the Board to pursue a political career, with his departure to be addressed at an Extraordinary General Meeting (EGM) on May 30. However, due to absences, the EGM was not legally convened, leaving the vacancy unfilled. The Annual General Meeting (AGM) was also delayed, extending the issue over the summer. The resignation was registered on July 2, but a clerical error misidentified the Chairman. In January 2025, Marinus Sørensen was appointed to fill a vacancy, but questions arose about the legality of the appointment, which was not registered with the Finnish Patent and Registration Office (PRH). Eevia is addressing these issues by updating registrations and planning elections at the upcoming General Meeting. Eevia Health Plc is a company that produces sustainable bioactive extracts from Nordic plants for global nutraceutical brands, focusing on health benefits. It operates in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, contact Stein Ulve, CEO of Eevia Health Plc.

Eevia Health Plc continues to face liquidity challenges, lacking access to new non-dilutive funding and unable to conduct equity issues. Despite these challenges, the company's restructuring plan is progressing, with slight revenue growth and new sales contracts that could support future growth. Eevia is also exploring sales opportunities with major global companies. Recent sales from inventory have generated cash, and significant cost reductions were made over the summer. Plans to relocate production to a new facility are underway, which could reduce future operational expenses. However, the company faces short debt maturities and insufficient cash flow to cover obligations. Creditors are demanding payments, and there is pressure to finalize repayment plans for statutory debts. The company's financial position has led to an evaluation of its going concern status and asset liquidation value, delaying the audit process and 2024 financial statements. Significant write-downs on assets have been agreed upon, affecting reported equity as of December 31, 2024, but these adjustments aim to secure an unqualified audit opinion. The audit report is expected by August 20, and a General Meeting will be called upon its receipt. Eevia Health specializes in sustainable bioactive extracts from Nordic plants and berries, focusing on gut, kidney, urinary health, cellular protection, and inflammation. Founded in 2017, it produces organic plant extracts, primarily from Finnish and Swedish forests, sold to global nutraceutical brands. Eevia is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.